Experimental antibody IC14 tested in rare heart condition
NCT ID NCT06275893
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested IC14 (atibuclimab), an antibody that targets inflammation, in one person with arrhythmogenic cardiomyopathy (ACM), a rare heart muscle disease that can cause dangerous heart rhythms. The study measured safety, blood markers of inflammation, and heart rhythm changes using the participant's implanted defibrillator and other tests. Because it involved only one participant and no placebo, the results are very preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IC14 (atibuclimab), a lab-made antibody targeting inflammation
What this could lead to
If it works, this could point toward a treatment that reduces inflammation and heart rhythm problems in people with arrhythmogenic cardiomyopathy.
What could go wrong
This is a very early, tiny trial with only 1 participant and no placebo group. It mainly checks safety, not effectiveness, so results may not apply to others.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States